|
|
Volumn 45, Issue 1, 2007, Pages 176-184
|
|
Development of LC/MS/MS assay for the determination of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one (SK3530) in human plasma: application to a clinical pharmacokinetic study
a
b
b
c
c
c
c
d
e
b
|
|
Author keywords
LC MS MS; PDE 5 inhibitor; Pharmacokinetics; SK3530; SK3541
|
|
Indexed keywords
5 ETHYL 2 [5 [4 (2 HYDROXYETHYL)PIPERAZINE 1 SULFONYL] 2 PROPOXYPHENYL] 7 PROPYL 3,5 DIHYDROPYRROLO[3,2 D]PYRIMIDIN 4 ONE;
DRUG METABOLITE;
PHOSPHODIESTERASE V INHIBITOR;
SK 3304;
SK 3530;
SK 3541;
UNCLASSIFIED DRUG;
ACCURACY;
ADULT;
AREA UNDER THE CURVE;
ARTICLE;
CONTROLLED STUDY;
CORRELATION COEFFICIENT;
DRUG BLOOD LEVEL;
DRUG DETERMINATION;
DRUG ELIMINATION;
DRUG HALF LIFE;
DRUG STABILITY;
ELECTROSPRAY MASS SPECTROMETRY;
HUMAN;
HUMAN EXPERIMENT;
LIQUID CHROMATOGRAPHY;
LIQUID LIQUID EXTRACTION;
MALE;
MAXIMUM PLASMA CONCENTRATION;
NORMAL HUMAN;
PRIORITY JOURNAL;
STANDARD;
TANDEM MASS SPECTROMETRY;
TIME TO MAXIMUM PLASMA CONCENTRATION;
VALIDATION STUDY;
ADMINISTRATION, ORAL;
ADULT;
CALIBRATION;
CHROMATOGRAPHY, HIGH PRESSURE LIQUID;
ERECTILE DYSFUNCTION;
HUMANS;
MALE;
MOLECULAR STRUCTURE;
PHARMACOLOGY, CLINICAL;
PYRIMIDINONES;
QUALITY CONTROL;
REFERENCE STANDARDS;
REPRODUCIBILITY OF RESULTS;
SENSITIVITY AND SPECIFICITY;
SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;
SULFONES;
TANDEM MASS SPECTROMETRY;
|
|
EID: 34548486958
PISSN: 07317085
EISSN: None
Source Type: Journal
DOI: 10.1016/j.jpba.2007.06.021 Document Type: Article |
|
Times cited : (10)
|
|
References (15)
|
